{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:20:52Z","timestamp":1780503652065,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Neurofibromatosis (NF) presents a significant clinical challenge due to its complex genetic basis, diverse clinical manifestation, and substantial impact on a patient\u2019s quality of life (QoL). This paper explores the multifaceted approach required to manage NF in Canada, emphasizing the integration of advanced diagnostic tools, targeted treatments, and comprehensive support systems. Healthcare providers, researchers, patient advocacy groups, and policymakers must collaborate to ensure NF patients receive the best possible care and support. This disease poses devastating consequences to families, and there has been a lack of awareness of this issue in Vancouver and, generally, in British Columbia. Currently, there is no clinic dedicated explicitly to NF in Metro Vancouver, and patients diagnosed with this disease must be flown to Toronto to get treated. The process is costly and inefficient, demanding changes. Some recent improvements in the field of NF have been noted, such as the use of gene therapy and MEK inhibitors. However, the long-term effect of this treatment is largely unknown and should be viewed with caution. This underscores the importance of enhancing psychological interventions to address the mental health challenges faced by NF patients. Specific gene sequences for different types of NF have also been mentioned in the article to offer insights on potential targets for gene-editing technology like CRISPR. Through ongoing advancements in medical science and a commitment to patient-centered care, this paper envisions significant improvements in the management and treatment of this complex condition.<\/jats:p>","DOI":"10.1186\/s13023-025-03793-2","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:07:59Z","timestamp":1754392079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From genes to therapy: navigating the complex landscape of neurofibromatosis management in Canada through advanced diagnostic, targeted therapies, and holistic care"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9895-5783","authenticated-orcid":false,"given":"Victor Shu Cheng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"3793_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2147\/JMDH.S454921","volume":"17","author":"FY Alshaikh","year":"2024","unstructured":"Alshaikh FY, et al. Epidemiology and outcomes of neurofibromatosis type 1. J Multidiscip Healthc. 2024;17:1303.","journal-title":"J Multidiscip Healthc"},{"issue":"1","key":"3793_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02493-5","volume":"17","author":"C Barnett","year":"2022","unstructured":"Barnett C, et al. Development of algorithms to identify individuals with neurofibromatosis type 1 within administrative data and electronic medical records in Ontario, Canada. Orphanet J Rare Dis. 2022;17(1):1\u2013321. https:\/\/doi.org\/10.1186\/s13023-022-02493-5.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3793_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","volume":"15","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, et al. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020;15(1):37\u201337. https:\/\/doi.org\/10.1186\/s13023-020-1310-3.","journal-title":"Orphanet J Rare Dis"},{"key":"3793_CR4","unstructured":"Brain Tumour Foundation of Canada. Neurofibromatosis type 1. Brain Tumour Foundation of Canada. 2021. Retrieved June 28, 2024, from https:\/\/www.braintumour.ca\/brain_tumour_types\/neurofibromatosis-type-1\/"},{"key":"3793_CR5","unstructured":"Brain Tumour Foundation of Canada. Neurofibromatosis type 2. Brain Tumour Foundation of Canada. 2021. Retrieved June 28, 2024, from https:\/\/www.braintumour.ca\/brain_tumour_types\/neurofibromatosis-type-2\/"},{"issue":"2","key":"3793_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41416-020-0903-x","volume":"123","author":"JP Brosseau","year":"2020","unstructured":"Brosseau JP, et al. Translating current basic research into future therapies for neurofibromatosis type 1. Br J Cancer. 2020;123(2):178\u201386. https:\/\/doi.org\/10.1038\/s41416-020-0903-x.","journal-title":"Br J Cancer"},{"key":"3793_CR7","unstructured":"Campian JL. Exploring new and novel treatments in neurofibromatosis. Oncology (Williston Park, N.Y.), 2020; 34(3): 75"},{"key":"3793_CR8","unstructured":"Canada NewsWire, PR Newswire Association LLC. KOSELUGOTM approved in Canada for pediatric patients with neurofibromatosis type 1 (NF1) plexiform neurofibromas (PN). 2023."},{"key":"3793_CR9","unstructured":"Canadian Cancer Society\/Soci\u00e9t\u00e9 canadienne du cancer. Neurofibromatosis type 1. Canadian Cancer Society. 2024. Retrieved June 28, 2024, from https:\/\/cancer.ca\/en\/cancer-information\/resources\/glossary\/n\/neurofibromatosis-type-1"},{"key":"3793_CR10","unstructured":"Canadian Skin Patient Alliance. Neurofibromatosis. Canadian Skin Patient Alliance. 2023. Retrieved June 28, 2024, from https:\/\/www.canadianskin.ca\/neurofibromatosis"},{"issue":"1","key":"3793_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13023-022-02195-y","volume":"17","author":"G Hamoy-Jimenez","year":"2022","unstructured":"Hamoy-Jimenez G, et al. A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1. Orphanet J Rare Dis. 2022;17(1):40\u201340. https:\/\/doi.org\/10.1186\/s13023-022-02195-y.","journal-title":"Orphanet J Rare Dis"},{"key":"3793_CR12","unstructured":"Health & Medicine Week, NewsRX LLC. New neurofibromatosis type 1 findings has been reported by researchers at University Health Network (quality of life in patients with neurofibromatosis type 1 and 2 in Canada). Health & Medicine Week, 2020: 3311"},{"key":"3793_CR13","unstructured":"Johns Hopkins Medicine. Schwannomatosis. Johns Hopkins Medicine. Retrieved June 28, 2024, from https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/neurofibromatosis\/schwannomatosis. 2022, March 10."},{"issue":"1","key":"3793_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-023-02911-2","volume":"18","author":"TSJ Lee","year":"2023","unstructured":"Lee TSJ, et al. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis. 2023;18(1):1\u2013292. https:\/\/doi.org\/10.1186\/s13023-023-02911-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3793_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1159\/000533144","volume":"48","author":"Y-T Lu","year":"2023","unstructured":"Lu Y-T, et al. Childhood-onset refractory hypertension results from neurofibromatosis type 1 caused by a splicing NF1 mutation. Kidney Blood Press Res. 2023;48(1):568\u201377. https:\/\/doi.org\/10.1159\/000533144.","journal-title":"Kidney Blood Press Res"},{"key":"3793_CR16","unstructured":"Myriad Canada - International Philanthropic Network. Ending NF2 through gene therapy. Myriad Canada - International Philanthropic Network. 2023, May 17 Retrieved June 28, 2024, from https:\/\/www.myriadcanada.org\/en\/project\/ending-nf2-through-gene-therapy\/"},{"issue":"12","key":"3793_CR17","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1038\/s41436-020-0925-z","volume":"22","author":"JA Perez-Valencia","year":"2020","unstructured":"Perez-Valencia JA, et al. Constitutional mismatch repair deficiency is the diagnosis in 0.41% of pathogenic NF1\/SPRED1 variant negative children suspected of sporadic neurofibromatosis type 1. Genet Med. 2020;22(12):2081\u20138. https:\/\/doi.org\/10.1038\/s41436-020-0925-z.","journal-title":"Genet Med"},{"issue":"3","key":"3793_CR18","doi-asserted-by":"publisher","first-page":"e476","DOI":"10.1542\/peds.2009-0152","volume":"124","author":"D Rea","year":"2009","unstructured":"Rea D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatr (Evanston). 2009;124(3):e476\u201383. https:\/\/doi.org\/10.1542\/peds.2009-0152.","journal-title":"Pediatr (Evanston)"},{"issue":"1","key":"3793_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00401-024-02724-y","volume":"147","author":"AO Stemmer-Rachamimov","year":"2024","unstructured":"Stemmer-Rachamimov AO, Kozanno L, Plotkin SR, Jordan JT, Rd Rizzo JF. Histologic correlates of \u201cChoroidal abnormalities\u201d in Neurofibromatosis type 1 (NF1). Acta Neuropathol. 2024;147(1):71. https:\/\/doi.org\/10.1007\/s00401-024-02724-y.","journal-title":"Acta Neuropathol"},{"issue":"Supplement_3","key":"3793_CR20","doi-asserted-by":"publisher","first-page":"iii418","DOI":"10.1093\/neuonc\/noaa222.608","volume":"22","author":"L Tam","year":"2020","unstructured":"Tam L, et al. NFB-04. Examining diffusion, arterial spin-labeled perfusion, and volumetric changes in the neurofibromatosis type 1 brain using an atlas-based, multi-parametric approach. Neuro-Oncol. 2020;22(Supplement_3):iii418\u2013iii418. https:\/\/doi.org\/10.1093\/neuonc\/noaa222.608.","journal-title":"Neuro-Oncol"},{"key":"3793_CR21","unstructured":"Tumour Foundation of BC. Schwannomatosis. Tumour Foundation of BC. Retrieved June 28, 2024. 2023, February 16. https:\/\/www.tumourfoundation.ca\/schwannomatosis\/"},{"key":"3793_CR22","unstructured":"Tumour Foundation of BC. NF1. Tumour Foundation of BC. 2024, April 23. Retrieved June 28, 2024. https:\/\/www.tumourfoundation.ca\/nf1\/"},{"key":"3793_CR23","unstructured":"Tumour Foundation of BC. NF2. Tumour Foundation of BC. Retrieved June 28, 2024. 2024, April 23. https:\/\/www.tumourfoundation.ca\/nf2\/"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03793-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:49:37Z","timestamp":1757357377000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03793-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3793"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03793-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"27 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that he has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"402"}}